Medical Doctor Program year 2024 Reported 2020–2024 Source: CMS Open Payments, 2026 publication

Lloyd Alderson

Neurology Leominster, MA Medical Doctor

NPI 1053368787 CMS profile 93190

50 Memorial Dr, Suite 211, Leominster, MA 01453

Open in the dashboard

General payments

$294

16 records reported · program years 2020–2024

Research payments

$0

Paid to them · None reported · program years 2020–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lloyd Alderson of Leominster, MA is reported in the CMS Open Payments database as having received $294 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $172 8
2023 General $66 4
2021 General $11 1
2020 General $45 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lloyd Alderson
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Lloyd Alderson were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Lloyd Alderson Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $45 $367 $82–$2,309 $114
2021 $11 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $66 $464 $119–$2,312 $160
2024 $172 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2024
  1. AbbVie, Inc. $133 7 payments
  2. Lundbeck LLC $87 4 payments
  3. Amneal Pharmaceuticals LLC $28 2 payments
  4. Allergan Inc. $26 2 payments
  5. Kyowa Kirin, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2024
  1. Food and Beverage $294 16 payments
Products named General payments · program years 2020–2024
  1. VYEPTI $87 4 payments
  2. QULIPTA $68 4 payments
  3. UBRELVY Neuroscience $65 3 payments
  4. RYTARY $28 2 payments
  5. UBRELVY Neuroscience $26 2 payments
  6. NOURIANZ $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

3,368

Median for Neurology: 833

Drug cost

$571,490

Median for Neurology: $202,670

Branded share of claims

28.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 33 $193,910
Aimovig Autoinjector Erenumab-Aooe Brand 55 $70,964
Copaxone Glatiramer Acetate Brand 12 $68,861
Ubrelvy Ubrogepant Brand 42 $43,084
Nurtec Odt Rimegepant Sulfate Brand 18 $27,564
Depakote Divalproex Sodium Brand 16 $15,902
Keppra Levetiracetam Brand 16 $14,834
Pregabalin Generic 150 $13,484
Ajovy Autoinjector Fremanezumab-Vfrm Brand 16 $12,586
Levetiracetam Generic 240 $10,891

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$87,159

Medicare's payments for the services billed

Medicare patients

545

Average age 75

Services billed

745

300 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 45%
Depression 27%
Ischemic heart disease 23%
Diabetes 20%
Atrial fibrillation 19%
Alzheimer's or dementia 19%
Chronic kidney disease 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
  • Lundbeck LLC $87
$87 — —
UBRELVY
  • AbbVie, Inc. $53
$53 42 —
QULIPTA
  • AbbVie, Inc. $17
$17 — —
RYTARY
  • Amneal Pharmaceuticals LLC $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record